Astedt B, Isacson S, Nilsson I M, Pandolfi M
Br Med J. 1973 Dec 15;4(5893):631-4. doi: 10.1136/bmj.4.5893.631.
The coagulation factors and components of the fibrinolytic system were examined in 31 women with a previous history of phlebographically-verified thrombosis during the use of oral contraceptives of the combined type. Special attention was given to the histochemically-determined fibrinolytic activator content of the wall of biopsy specimens of superficial veins. None of the patients was taking contraceptives at the time of the investigation. Pathological changes, particularly in the fibrinolytic defence system, were found in most of the patients. They may be regarded as predisposed to thrombosis, and one might wonder whether these patients would sooner or later have had their thrombosis even if they had not used contraceptives. The concentration of antithrombin III was normal, indicating that this test is of no value for detecting patients predisposed to thrombosis, who should preferably not take oral contraceptives.
对31名有静脉造影证实的血栓形成病史的女性在使用复方口服避孕药期间的凝血因子和纤溶系统成分进行了检查。特别关注了浅静脉活检标本壁组织化学测定的纤溶激活剂含量。调查时所有患者均未服用避孕药。大多数患者发现有病理变化,尤其是在纤溶防御系统。他们可能被视为易患血栓形成,有人可能会想,即使这些患者没有使用避孕药,他们迟早是否也会发生血栓形成。抗凝血酶III浓度正常,表明该检测对检测易患血栓形成的患者没有价值,这些患者最好不要服用口服避孕药。